Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory…
| Periodo | 2027-02 | 2023-08 | 2023-05 | 2023-02 |
|---|---|---|---|---|
| Real | — | $-0.29 | $-0.25 | $-0.33 |
| Estimado | — | $-0.30 | $-0.32 | $-0.28 |
| Sorpresa | — | +3.3% | +21.9% | -17.9% |
| Métrica | MESO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 70.2% | 57.4% | +12.8% |
| Operating Margin | — | -34.4% | — |
| Net Margin | -593.9% | -32.5% | -561.5% |
| FCF Margin | -294.4% | -12.6% | -281.8% |
| ROE | -17.1% | -39.2% | +22.1% |
| ROA | -13.0% | -30.9% | +17.9% |
| Current Ratio | 1.99 | 2.73 | -0.74 |
| Debt / Equity | 0.11 | 0.28 | -0.17 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -13.0% | — |
| ✗Flujo de caja operativo positivo | −$50M | −$48M |
| ✓Rentabilidad sobre activos al alza | -13.0% | -13.1% |
| ✓Caja operativa/activos supera al ROA | -6.4% | ROA -13.0% |
| ✓Menos deuda a largo plazo | 8.6% | 15.0% |
| ✓Mejor liquidez (ratio corriente) | 1.99 | 1.18 |
| ✗Sin aumentar el nº de acciones | 1,208M | 987M |
| ✗Margen bruto al alza | 70.2% | 100.0% |
| ✓Rotación de activos al alza | 0.02 | 0.01 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -294.4% |
| ✓Ventas > 5 %/año (3 años) | 19.0% |
| ✓Deuda neta/EBITDA < 3x | Caja neta |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 206.3% |
MESOBLAST LTD cotiza a 13.28 USD y tiene una capitalización bursátil de $1.7B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud